Payment overview · 2025
General Payments
$3,903.91
195 reported records · 15 companies
Healthcare provider profile · identity verified
Lisa Haut
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · TORRINGTON, CT · NPI 1962400150
Verified facts
What the public records show
CMS Open Payments records show Lisa Haut received $3,903.91 in general payments during 2025 across 195 reported records.
ABBVIE INC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Rexulti, Spravato, Vivitrol, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vivitrol by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Auvelity by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Spravato by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,282.90 | 32.9% | 67 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $1,178.36 | 30.2% | 59 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $405.28 | 10.4% | 22 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $265.61 | 6.8% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $225.39 | 5.8% | 15 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $106.78 | 2.7% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $76.54 | 2.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.29 | 1.9% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $64.90 | 1.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.49 | 1.6% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $51.39 | 1.3% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $42.44 | 1.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.16 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.82 | 0.6% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $13.56 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,903.91 | 195 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,178.36 | 59 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $917.79 | 46 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $405.28 | 22 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $365.11 | 21 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $265.61 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $242.37 | 20 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $139.78 | 6 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $136.66 | 9 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $106.78 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $88.73 | 6 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $64.90 | 3 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $57.27 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $51.39 | 3 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $42.44 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SPRAVATO spravato |
2025 | Spravato | 2024 | 81 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VIVITROL vivitrol |
2025 | Vivitrol | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 117 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
117 | 19 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SPRAVATO open payments reported associated product |
CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254 |
Spravato · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 206 | 25 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 194 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 181 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 177 | 20 |
| Gabapentin | Gabapentin | 165 | 22 |
| Lorazepam | Lorazepam | 143 | 11 |
| Alprazolam | Alprazolam | 140 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 117 | 19 |
| Vraylar | Cariprazine Hcl | 117 | 19 |
| Bupropion Xl | Bupropion Hcl | 107 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 100 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 16 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 85 | suppressed |
| Lisinopril | Lisinopril | 82 | 14 |
| Spravato | Esketamine Hcl | 81 | suppressed |
| Ibuprofen | Ibuprofen | 74 | 14 |
| Mirtazapine | Mirtazapine | 66 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 58 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | suppressed |
| Ondansetron Odt | Ondansetron | 56 | suppressed |
| Olanzapine | Olanzapine | 55 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 51 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 49 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 49 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Rexulti | Brexpiprazole | 40 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 37 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 25 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Losartan Potassium | Losartan Potassium | 22 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Vivitrol | Naltrexone Microspheres | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,903.91 · 195 records | ABBVIE INC. | AUSTEDO XR, Auvelity, Azstarys, BRIXADI, CAPLYTA, Epclusa, INGREZZA, QULIPTA, REXULTI, SPRAVATO, SUBLOCADE, TRINTELLIX, UBRELVY, UZEDY, VIVITROL, VRAYLAR, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error